---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-022762"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:16:58.181101+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027

## Summary
- Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.
- Net loss $121.3M includes $79.3M loss from excess of warrant fair value over private placement proceeds and $27.5M acquired IPR&D expense.
- Closed private placement for up to $185M gross; initial $115.6M received; warrants classified as liability with $194.9M fair value.
- Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026; trial to start this year.
- Strategic review underway for quisovalimab (AVTX-002) and AVTX-008 programs; no revenue in Q1 2024 vs $475K a year ago.

## SEC filing metadata
- accession: 0001628280-24-022762
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/0001628280-24-022762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/avtx-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-022762
- JSON: https://secwatch.observer/filing/0001628280-24-022762.json
- Plain text: https://secwatch.observer/filing/0001628280-24-022762.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported first quarter of 2024 results: net income net loss of $121.3 million.
  - Period: first quarter of 2024
  - Net income: net loss of $121.3 million
  - Result: reported results
  source text: For the three months ended March 31, 2024, Avalo generated a net loss of $121.3 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/0001628280-24-022762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.